Liposome-Encapsulated Hemoglobin Vesicle Improves Persistent Anti-arrhythmogenesis through Improving Myocardial Electrical Remodeling and Modulating Cardiac Autonomic Activity in a Hemorrhagic Shock-Induced Rat Heart Model

Abstract

Objective

Shock heart syndrome (SHS) is associated with lethal arrhythmias (ventricular tachycardia/ventricular fibrillation, VT/VF). We investigated whether liposome-encapsulated human hemoglobin vesicles (HbVs) has comparable persistent efficacy to washed red blood cells (wRBCs) for improving arrhythmogenesis in the subacute to chronic phase of SHS.

Methods

Optical mapping analysis (OMP), electrophysiological study (EPS), and pathological examinations were performed on blood samples from Sprague-Dawley rats following induction of hemorrhagic shock. After hemorrhagic shock, the rats were immediately resuscitated by transfusing 5% albumin (ALB), HbV, or wRBCs. All rats survived for 1 week. OMP and EPS were performed on Langendorff-perfused hearts. Spontaneous arrhythmias and heart rate variability (HRV) were evaluated using awake 24-h telemetry, cardiac function by echocardiography, and pathological examination of Connexin43.

Results

OMP showed significantly impaired action potential duration dispersion (APDd) in the left ventricle (LV) in the ALB group whereas APDd was substantially preserved in the HbV and wRBCs groups. Sustained VT/VF was easily provoked by EPS in the ALB group. No VT/VF was induced in the HbV and wRBCs groups. HRV, spontaneous arrhythmias, and cardiac function were preserved in the HbV and wRBCs groups. Pathology showed myocardial cell damage and Connexin43 degradation in the ALB group, all of which were attenuated in the HbV and wRBCs groups.

Conclusion

LV remodeling after hemorrhagic shock caused VT/VF in the presence of impaired APDd. Similar to wRBCs, HbV persistently prevented VT/VF by inhibiting persistent electrical remodeling, preserving myocardial structures, and ameliorating arrhythmogenic modifying factors in the subacute to chronic phase of hemorrhagic shock-induced SHS.

Keywords

artificial oxygen carrier / hemorrhage / lethal arrhythmia / resuscitation / heart rate variability

References

[1] SolimanM. Dimethyl amiloride, a Na+-H+ exchange inhibitor, and its cardioprotective effects in hemorrhagic shock in in vivo resuscitated rats. J Physiol Sci, 2009, 59(3): 175-180

[2] MiyazakiK, HoriS, InoueS, et al.. Characterization of energy metabolism and blood flow distribution in myocardial ischemia in hemorrhagic shock. Am J Physiol, 1997, 273(2): H600-H607Pt 2

[3] AdachiT, HoriS, MiyazakiK, et al.. Inhibition of nitric oxide synthesis aggravates myocardial ischemia in hemorrhagic shock in constant pressure model. Shock, 1998, 9(3): 204-209

[4] ThackerSA, RobinsonP, AbelA, et al.. Modulation of the unfolded protein response during hepatocyte and cardiomyocyte apoptosis in trauma/hemorrhagic shock. Sci Rep, 2013, 3: 1187

[5] LiW, WangX, HeM, et al.. Activating Na+-K+ ATPase: a potential cardioprotective therapy during early hemorrhagic shock. Med Hypotheses, 2014, 83(6): 685-687

[6] ChatpunS, CabralesP. Cardiac systolic function recovery after hemorrhage determines survivability during shock. J Trauma, 2011, 70(4): 787-793

[7] McKinleyTO, McCarrollT, MetzgerC, et al.. Shock volume: Patient-specific cumulative hypoperfusion predicts organ dysfunction in a prospective cohort of multiply injured patients. J Trauma Acute Care Surg, 2018, 85(Suppl 2): S84-S91 1S

[8] TakaseB, HigashimuraY, HashimotoK, et al.. Myocardial Electrical Remodeling and the Arrhythmogenic Substrate in Hemorrhagic Shock-Induced Heart: Anti-Arrhythmogenic Effect of Liposome-Encapsulated Hemoglobin (HbV) on the Myocardium. Shock, 2019, 52(3): 378-386

[9] SakaiH, MasadaY, HorinouchiH, et al.. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med, 2004, 32(2): 539-545

[10] SakaiH, TomiyamaK, MasadaY, et al.. Pretreatment of serum containing hemoglobin vesicles (oxygen carriers) to prevent their interference in laboratory tests. Clin Chem Lab Med, 2003, 41(2): 222-231

[11] SakaiH, TsaiAG, KergerH, et al.. Subcutaneous microvascular responses to hemodilution with a red cell substitute consisting of polyethyleneglycol-modified vesicles encapsulating hemoglobin. J Biomed Mater Res, 1998, 40(1): 66-78

[12] PhillipsWT, KlipperRW, AwasthiVD, et al.. Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther, 1999, 288(2): 665-670

[13] ZarzosoM, MironovS, Guerrero-SernaG, et al.. Ventricular remodelling in rabbits with sustained high-fat diet. Acta Physiol (Oxf), 2014, 211(1): 36-47

[14] ChengY, MowreyKA, NikolskiV, et al.. Mechanisms of shock-induced arrhythmogenesis during acute global ischemia. Am J Physiol Heart Circ Physiol, 2002, 282(6): H2141-H2151

[15] WilsonLD, JeyarajD, WanX, et al.. Heart failure enhances susceptibility to arrhythmogenic cardiac alternans. Heart Rhythm, 2009, 6(2): 251-259

[16] Bloch ThomsenPE, JonsC, et al.. Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) Study Group. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation, 2010, 122(13): 1258-1264

[17] LeeHB, BlaufoxMD. Blood volume in rat. J Nucl Med, 1985, 26(1): 72-76

[18] CannonJW. Hemorrhagic Shock. N Engl J Med, 2018, 378(4): 370-379

[19] SeishiY, HorinouchiH, SakaiH, et al.. Effect of the cellular-type artificial oxygen carrier hemoglobin vesicle as a resuscitative fluid for prehospital treatment: experiments in a rat uncontrolled hemorrhagic shock model. Shock, 2012, 38(2): 153-158

[20] SakaiH, SeishiY, ObataY, et al.. Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. Shock, 2009, 31(2): 192-200

[21] HagisawaK, KinoshitaM, SaitohD, et al.. Intraosseous transfusion of hemoglobin vesicles in the treatment of hemorrhagic shock with collapsed vessels in a rabbit model. Transfusion, 2020, 60(7): 1400-1409

[22] DuttaS, MincholéA, QuinnTA, et al.. Electrophysiological properties of computational human ventricular cell action potential models under acute ischemic conditions. Prog Biophys Mol Biol, 2017, 129: 40-52

[23] GlukhovAV, FedorovVV, LouQ, et al.. Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ Res, 2010, 106(5): 981-989

[24] Al-ZaitiSS, CallawayCW, KozikTM, et al.. Clinical Utility of Ventricular Repolarization Dispersion for Real-Time Detection of Non-ST Elevation Myocardial Infarction in Emergency Departments. J Am Heart Assoc, 2014, 4(7): e002057

[25] TanakaY, TakaseB, YaoT, et al.. Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension. Am J Respir Cell Mol Biol, 2013, 49(3): 426-436

[26] NogamiY, TakaseB, MatsuiT, et al.. Effect of antiarrhythmic agents on heart rate variability indices after myocardial infarction: comparative experimental study of aprindine and procainamide. Biomed Pharmacother, 2005, 59(Suppl 1): S169-173

[27] MallianiA, PaganiM, LombardiF, et al.. Spectral analysis to assess increased sympathetic tone in arterial hypertension. Hypertension, 1991, 17: III36-42 4 Suppl

[28] BoluytMO, ConversoK, HwangHS, et al.. Echocardiographic assessment of age-associated changes in systolic and diastolic function of the female F344 rat heart. J Appl Physiol, 2004, 96(2): 822-828

[29] MossAJ, ZarebaW, HallWJ, et al.. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002, 346(12): 877-883

[30] BardyGH, LeeKL, MarkDB, et al.. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. N Engl J Med, 2005, 352(3): 225-237

[31] KoyakZ, de GrootJR, BoumaBJ, et al.. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen?. Europace, 2017, 19(3): 401-406

[32] KirbasA, KirbasO, DaglarK, et al.. Novel indexes of arrhythmogenesis in preeclampsia: QT dispersion, Tp-e interval, and Tp-e/QT ratio. Pregnancy Hypertens, 2016, 6(1): 38-41

[33] MeoM, MesteO, SignoreS, et al.. Reduction in Kv Current Enhances the Temporal Dispersion of the Action Potential in Diabetic Myocytes: Insights From a Novel Repolarization Algorithm. J Am Heart Assoc, 2016, 5(2): e003078

[34] ShuC, HuangW, ZengZ, et al.. Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes. Anatol J Cardiol, 2017, 18(1): 3-9

[35] PoelzingS, RosenbaumDS. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol, 2004, 287(4): H1762-H1770

[36] WitAL, JanseMJ. Reperfusion arrhythmias and sudden cardiac death: a century of progress toward an understanding of the mechanisms. Circ Res, 2001, 89(9): 741-743

[37] TaguchiK, MiyasatoM, WatanabeH, et al.. Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity. J Pharm Sci, 2011, 100(2): 775-783

[38] NatansonC, KernSJ, LurieP, et al.. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA, 2008, 299(19): 2304-2312

[39] BurhopK, GordonD, EstepT. Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol, 2004, 32(3): 353-374

[40] SakaiH. Present situation of the development of cellular-type hemoglobin-based oxygen carrier (hemoglobin-vesicles). Curr Drug Discov Technol, 2012, 9(3): 188-193

[41] TakeokaS, TeramuraY, AtojiT, et al.. Effect of Hb-encapsulation with vesicles on H2O2 reaction and lipid peroxidation. Bioconjug Chem, 2002, 13(6): 1302-1308

[42] SakaiH, SouK, HorinouchiH, et al.. Hemoglobin-vesicle, a cellular artificial oxygen carrier that fulfils the physiological roles of the red blood cell structure. Adv Exp Med Biol, 2010, 662: 433-438

[43] YadavVR, RaoG, HousonH, et al.. Nanovesicular liposome-encapsulated hemoglobin (LEH) prevents multi-organ injuries in a rat model of hemorrhagic shock. Eur J Pharm Sci, 2016, 93: 97-106

[44] TaguchiK, UrataY, AnrakuM, et al.. Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier. Drug Metab Dispos, 2009, 37(7): 1456-1463

[45] KanedaS, IshizukaT, GotoH, et al.. Liposome-Encapsulated Hemoglobin, TRM-645: Current Status of the Development and Important Issues for Clinical Application. Artif Organs, 2009, 33(2): 146-152

[46] NogamiY, TakaseB, KinoshitaM, et al.. Liposome-encapsulated hemoglobin attenuates cardiac dysfunction and sympathetic activity during hypohemoglobinemic shock. Shock, 2012, 38(2): 159-164

[47] HuikuriHV, RaatikainenMJ, Moerch-JoergensenR, et al.. Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction study group. Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J, 2009, 30: 689-698

[48] ChenJY, ScerboM, KramerG. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo), 2009, 64(8): 803-813

[49] JahrJS, MackenzieC, PearceLB, et al.. HBOC-201 as an Alternative to Blood Transfusion: Efficacy and Safety Evaluation in a Multicenter Phase III Trial in Elective Orthopedic Surgery. J Trauma, 2008, 64(6): 1484-1497

[50] GouldSA, MooreEE, HoytDB, et al.. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg, 1998, 187(2): 113-120

[51] JahrJS, AkhaAS, HoltbyRJ. Crosslinked, polymerized, and PEG-conjugated hemoglobin-based oxygen carriers: clinical safety and efficacy of recent and current products. Curr Drug Discov Technol, 2012, 9(3): 158-165